225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models

PURPOSE: Despite the availability of new drugs, many patients with acute myeloid leukemia (AML) do not achieve remission and outcomes remain poor. Venetoclax is a promising new therapy approved for use in combination with a hypomethylating agent or with low‐dose cytarabine for the treatment of newly...

Descripción completa

Detalles Bibliográficos
Autores principales: Garg, Ravendra, Allen, Kevin J. H., Dawicki, Wojciech, Geoghegan, Eileen M., Ludwig, Dale L., Dadachova, Ekaterina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897952/
https://www.ncbi.nlm.nih.gov/pubmed/33347715
http://dx.doi.org/10.1002/cam4.3665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897952/
https://www.ncbi.nlm.nih.gov/pubmed/33347715
http://dx.doi.org/10.1002/cam4.3665

Ejemplares similares